Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + R-GDP in TP53-altered R/R DLBCL
NCT06062641Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06062641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062641.